Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

‘NYTimes To Buy The Athletic for $550 Million’ -The Information

https://www.theinformation.com/articles/nyt-to-buy-the-athletic-for-550-million

byBenzinga Newsdesk

January 6, 2022

1 minute read

https://www.theinformation.com/articles/nyt-to-buy-the-athletic-for-550-million

SIGA Technologies Shares Move Higher; Pittsburgh Reports First Case Of Monkeypox

By Benzinga Newsdesk

Today, 10:08 PM

https://www.wtrf.com/top-stories/pittsburgh-has-its-first-case-of-monkeypox/?utm_source=t.co&utm_campaign=socialflow&utm_medium=referral

AEMD

WISeKey Announces Sale Of Its 51% Stake In ARAGO For EUR 25.5M

By Benzinga Newsdesk

Today, 10:08 PM

WISeKey Announces the Sale of its 51% Stake in ARAGO for EUR 25.5 Million WISeKey Announces the Sale of its 51% Stake in ARAGO for EUR 25.5

WKEY

Cybin’s Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

By Lara Goldstein

Today, 10:08 PM

Psychedelic biopharma company Cybin Inc. (NEO: CYBN) has received FDA Investigational New Drug Application (IND) approval for a Phase 1/2a clinical trial evaluating its proprietary CYB003 for treating major depressive disorder (MDD).

CYBN

RBC Capital Initiates Coverage On TaskUs with Outperform Rating, Announces Price Target of $43

By Benzinga Newsdesk

Today, 10:08 PM

RBC Capital analyst Daniel Perlin initiates coverage on TaskUs (NASDAQ:TASK) with a Outperform rating and announces Price Target of $43.

TASK

‘NYTimes To Buy The Athletic for $550 Million’ -The Information

Related Posts

SIGA Technologies Shares Move Higher; Pittsburgh Reports First Case Of Monkeypox

WISeKey Announces Sale Of Its 51% Stake In ARAGO For EUR 25.5M

Cybin’s Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder

RBC Capital Initiates Coverage On TaskUs with Outperform Rating, Announces Price Target of $43